AMPLY Discovery

AMPLY Discovery is a biotech company using artificial intelligence, machine learning and wet-lab validation to discover novel medicines from underexplored areas of the genome. Its TALON platform combines specialist engines for target discovery, druggability assessment, antisense and siRNA therapeutic design, primer design, and antimicrobial biologics discovery. The company focuses on hard-to-treat diseases, with programmes in oncology and drug-resistant infections, including triple-negative breast cancer, acute myeloid leukaemia, multidrug-resistant tuberculosis and cystic fibrosis lung infections. AMPLY works across computational biology, synthetic biology and translational drug discovery, supporting pharmaceutical and biotech partners with experimentally validated therapeutic programmes.